Open AccessEstablishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells
Author(s) -
Ryuji Ikeda,
Lee C. Vermeulen,
Elim Lau,
Zhisheng Jiang,
Marcia Pomplun,
Jill Kolesar
Publication year - 2010
Publication title -
molecular medicine reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.727
H-Index - 56
eISSN - 1791-3004
pISSN - 1791-2997
DOI - 10.3892/mmr.2010.366
Subject(s) - irinotecan , a549 cell , cancer research , gemcitabine , carboplatin , lung cancer , camptothecin , oncogene , apoptosis , cancer , medicine , chemistry , cell cycle , biology , colorectal cancer , chemotherapy , oncology , cisplatin , biochemistry
Irinotecan (CTP-11) is a topoisomerase I inhibitor used in the treatment of colorectal cancer and non-small cell lung cancer (NSCLC). Despite an initial response to therapy, resistance to irinotecan reduces its efficacy. We isolated irinotecan-resistant human NSCLC A549 cells, termed A549/CTP-11R cells. A549/CTP-11R cells were resistant to irinotecan, as well as paclitaxel, gemcitabine and carboplatin. Curcumin, a nuclear factor-κB (NF-κB) inhibitor, increased the sensitivity to irinotecan of A549/CTP-11R cells. The expression level of Bcl-XL and X-linked inhibitor of apoptosis protein, target genes of NF-κB, in A549/CTP-11R cells was higher than that in A549 cells. Our result suggests that the addition of curcumin to irinotecan reverses irinotecan resistance in NSCLC.